Dengue vaccine analysis: Anvisa requests clarifications and technical data

News Healthcare & Pharma General Updates

Date: 11th Feb, 2025 Source: National Health Surveillance Agency (Anvisa) Country: Brazil Original Source

Brief

On 11/02/2025, the National Health Surveillance Agency (Anvisa) issued an update regarding Dengue vaccine analysis: Anvisa requests clarifications and technical data. The agency completed its pre-emptive quality, safety, and efficacy analysis of the dengue vaccine developed by the Butantan Institute, requesting supplementary information and data to proceed with the review process.

This content is restricted.

Highlights content goes here...

This content is restricted.

National Health Surveillance Agency (Anvisa)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Dengue vaccine analysis: Anvisa requests clarifications and technical data

Brief

National Health Surveillance Agency (Anvisa)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Dengue vaccine analysis: Anvisa requests clarifications and technical data

Brief

National Health Surveillance Agency (Anvisa)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.